Jason B. Daly - 05 Mar 2025 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: EVP, Chief Legal Officer
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol: AMRX
Transactions as of: 05 Mar 2025
Net transactions value: -$792,160
Form type: 4
Filing time: 07 Mar 2025, 16:17:53 UTC
Previous filing: 05 Mar 2025
Next filing: 13 Aug 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Sale	$382,408	-43,064	-35%	$8.88	79,542	05 Mar 2025	Direct	F1
transaction	AMRX	Class A Common Stock	Sale	$409,751	-46,936	-59%	$8.73	32,606	06 Mar 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.62 to $9.00 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
F2	The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.64 to $8.84 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

Content

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.62 to $9.00 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.64 to $8.84 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.